Aquaporin-4 autoimmunity

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 4, 2015, Pages

  Zekeridou, Anastasia ^a   Lennon, Vanda A ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PREDNISONE;

AUTOIMMUNITY; CEREBROSPINAL FLUID; CIRCUMVENTRICULAR ORGAN; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IN VITRO STUDY; MYELITIS; MYELOOPTIC NEUROPATHY; NONHUMAN; OPTIC NEURITIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKELETAL MUSCLE;

EID: 84955355151     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000110     Document Type: Review

References (60)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
5. Mao Z, Lu Z, Hu X, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 83: 1122.
6. Tzartos JS, Stergiou C, Kilidireas K, Zisimopoulou P, Thomaidis T, Tzartos SJ. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One 2013; 8: e74773.
7. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69: 1176-1180.
8. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76: 1589-1595.
9. Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74: 736-742.
10. Apiwattanakul M, Asawavichienjinda T, Pulkes T. Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory diseases in Thai patients. J Neurol Sci 2012; 320: 118-120.
11. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011; 82: 1360-1364.
12. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
13. Quek AM, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012; 69: 1039-1043.
14. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14.
15. Matiello M, Schaefer-Klein JL, Hebrink DD, Kingsbury DJ, Atkinson EJ, Weinshenker BG. Genetic analysis of aquaporin-4 in neuromyelitis optica. Neurology 2011; 77: 1149-1155.
16. Devic E. Myélite subaiguë compliquée de névrite optique. Le Bulletin Médical 1894; 8: 1033-1034.
17. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853.
18. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603-605.
19. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72: 81-87.
20. Takai Y, Misu T, Nakashima I, et al. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 2012; 79: 1826-1828.
21. Guo Y, Lennon VA, Popescu BF, et al. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 2014; 71: 1025-1029.
22. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008; 65: 629-632.
23. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
24. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968.
25. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody. J Neurol 2009; 256: 287-288.
26. Iorio R, Plantone D, Damato V, Paola Batocchi A. Anorexia heralding the onset of neuromyelitis optica. Intern Med 2013; 52: 489-491.
27. Iorio R, Lucchinetti CF, Lennon VA, et al. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology 2011; 77: 1644-1646.
28. Vernant JC, Cabre P, Smadja D, et al. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997; 48: 58-64.
29. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler Epub 2013 Oct 7.
30. Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72: 712-717.
31. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71: 93-100.
32. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83.
33. Long Y, Zheng Y, Chen M, et al. Serum thyroidstimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases. PLoS One 2014; 9: e100672.
34. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009; 39: 87-90.
35. Bergamaschi R, Jarius S, Robotti M, Pichiecchio A, Wildemann B, Meola G. Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 2009; 256: 2097-2099.
36. Jarius S, Paul F, Ruprecht K, Wildemann B. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 2012; 259: 2743-2745.
37. Ontaneda D, Fox RJ. Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder? Int J Neurosci 2014; 124: 509-511.
38. Chan KH, Kwan JS, Ho PW, et al. Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. J Neuroimmunol 2010; 227: 178-184.
39. Armagan H, Tüzün E, Içöz S, et al. Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: favorable response to cancer treatment. J Spinal Cord Med 2012; 35: 267-269.
40. Figueroa M, Guo Y, Tselis A, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol 2014; 71: 495-498.
41. Frasquet M, Bataller L, Torres-Vega E, et al. Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma. J Neuroimmunol 2013; 263: 145-147.
42. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-461.
43. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283.
44. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler Epub 2014 Oct 24; pii: 1352458514555785.
45. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273-1277.
46. Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015; 21: 656-659.
47. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75: 208-216.
48. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2: e62. doi: 10.1212/NXI.0000000000000062.
49. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008; 255: 163-170.
50. Klawiter EC, Xu J, Naismith RT, et al. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler 2012; 18: 1259-1268.
51. Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013; 33: 123-127.
52. Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014; 10: 447-458.
53. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011; 306: 82-90.
54. Brickshawana A, Hinson SR, Romero MF, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2014; 13: 795-806.
55. Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428.
56. Long Y, Zheng Y, Shan F, et al. Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. J Neuroimmunol 2014; 273: 103-110.
57. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671.
58. Fryer JP, Lennon VA, Pittock SJ, et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014; 1: e11. doi: 10.1212/NXI.0000000000000011.
59. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMOIgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013; 23: 661-683.
60. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-1849.